Mendelian susceptibility to mycobacterial disease (IFNGR1 interferon-gamma-receptor deficiency) OMIM 209950
In Mendelian susceptibility to mycobacterial disease (IFNGR1, OMIM 209950), the master switch sits on the ↓ DOWN branch ([F] forced below); the healthy state is the ON well. The forced corrective direction is to raise s toward ON branch (polarity: supply). Classification: — Honest hold (no matched agent). Direction only — no dose, no efficacy magnitude.
The disease maps to an R19 double-well whose corrective lever is read straight off the cusp (barrier 0.4798, γ 1.3854, spinodal 0.6276). The corrective direction is forced [F]; the agent names below are direction-concordant labels at grade [O] (no dose, no efficacy or safety magnitude). This is a research hypothesis offered to experts, not medical advice.
The emergence switch
The switch for Mendelian susceptibility to mycobacterial disease is an R19 double-well emerged from the real proximal-promoter DNA of IFNGR1. Its geometry is fixed by measured stiffness γ (never fitted); the numbers below are read directly off that cusp.
- emergent axis
- ↓ DOWN [F]
- healthy branch
- ON
- lesion
- LOF_null
- γ (stiffness)
- 1.3854
- barrier
- 0.4798
- spinodal
- 0.6276
- s_on / s_off
- 1.1770 / -1.1770
- fragility
- 0.55
- corrective polarity
- supply
- forced direction
- raise s toward ON branch
Chemistry feasibility (DIRECTION only [O]). small-molecule recrossing of the fold is geometrically plausible (barrier 0.4798 at neutral drive; lower barrier = smaller drive to supply). [O] -- no affinity/potency/dose/efficacy asserted.
The derived corrective lever
The cusp forces a corrective direction: raise s toward ON branch. This is the load-bearing output of the framework — it is [F] forced, and it is falsifiable. 2 lever families are derived; the lead is h-restore (drive modulator).
Agents mapped onto the lever
| agent (class) | dir. | status | phase | map |
|---|---|---|---|---|
| interferon-gamma-axis signalling functional supply (definitive management for complete deficiency is haematopoietic reconstitution; no direction-matched small-molecule agent applies) Newport 1996 N Engl J Med 335:1941; Jouanguy 1996 N Engl J Med 335:1956 | increase | research | 0 | ◇ in trials |
Evidence & provenance
| element | grade | basis |
|---|---|---|
| R19 switch & cusp geometry (this page) | [V] verified | emerged from measured promoter γ of IFNGR1; deterministic, 2×sha256 identical |
| corrective direction | [F] forced | forced by the cusp sign; falsifiable (see lever falsifiers) |
| mapped agents / leads | [O] open | direction-concordance only; corpus-pinned (2026-06-21); no dose, no efficacy/safety magnitude |
Reading the agent column. VALIDATION SIGNAL -- the agent is already approved / established standard for this disease, so the direction logic recovered known clinical practice. Not a new claim by this kit. GENUINE HYPOTHESIS -- no approved indication for this disease; the direction match is a direction-only, untested [O] lead. Basis field grades the evidence (investigational here / in a related condition / off-label / speculative).